PharmaCyte Biotech, Inc.
PMCB
$0.72
-$0.03-3.73%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.03M | 1.24M | 753.10K | 915.10K | 842.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.12M | 1.38M | 848.30K | 1.04M | 960.30K |
| Operating Income | -2.12M | -1.38M | -848.30K | -1.04M | -960.30K |
| Income Before Tax | 746.90K | -7.42M | -8.36M | 11.75M | -3.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 746.90K | -7.42M | -8.36M | 11.75M | -3.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 746.90K | -7.42M | -8.36M | 11.75M | -3.05M |
| EBIT | -2.12M | -1.38M | -848.30K | -1.04M | -960.30K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.17 | -1.24 | -1.23 | 1.58 | -0.44 |
| Normalized Basic EPS | -0.06 | -0.65 | -0.50 | -0.10 | -0.01 |
| EPS Diluted | -0.17 | -1.24 | -1.23 | 1.58 | -0.44 |
| Normalized Diluted EPS | -0.06 | -0.65 | -0.50 | -0.10 | -0.01 |
| Average Basic Shares Outstanding | 9.26M | 6.80M | 6.80M | 6.85M | 6.96M |
| Average Diluted Shares Outstanding | 9.26M | 6.80M | 6.80M | 6.85M | 6.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 13.57% | -0.83% | -- | -- | -- |